A miRNA-based Signature Predicts Development of Disease Recurrence in HER2 Positive Breast Cancer After Adjuvant Trastuzumab-Based Treatment

Scientific Reports - United Kingdom
doi 10.1038/srep33825
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC


Related search